SE518619C2 - Komposition för reglerad frisättning innehållande monokaproin - Google Patents

Komposition för reglerad frisättning innehållande monokaproin

Info

Publication number
SE518619C2
SE518619C2 SE9404289A SE9404289A SE518619C2 SE 518619 C2 SE518619 C2 SE 518619C2 SE 9404289 A SE9404289 A SE 9404289A SE 9404289 A SE9404289 A SE 9404289A SE 518619 C2 SE518619 C2 SE 518619C2
Authority
SE
Sweden
Prior art keywords
composition
composition according
mixture
biologically active
monocaproin
Prior art date
Application number
SE9404289A
Other languages
English (en)
Swedish (sv)
Other versions
SE9404289L (sv
SE9404289D0 (sv
Inventor
Kaare Larsson
Helena Ljusberg-Wahren
Original Assignee
Gs Dev Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Dev Ab filed Critical Gs Dev Ab
Priority to SE9404289A priority Critical patent/SE518619C2/sv
Publication of SE9404289D0 publication Critical patent/SE9404289D0/xx
Priority to BR9509897A priority patent/BR9509897A/pt
Priority to CA002207218A priority patent/CA2207218C/en
Priority to FI972415A priority patent/FI972415A7/fi
Priority to EP95941306A priority patent/EP0790822B1/de
Priority to AT95941306T priority patent/ATE213932T1/de
Priority to AU42768/96A priority patent/AU4276896A/en
Priority to US08/836,103 priority patent/US5906831A/en
Priority to ES95941306T priority patent/ES2170171T3/es
Priority to PCT/SE1995/001479 priority patent/WO1996017597A1/en
Priority to DE69525761T priority patent/DE69525761T2/de
Priority to JP51754296A priority patent/JP3487860B2/ja
Publication of SE9404289L publication Critical patent/SE9404289L/xx
Priority to NO972614A priority patent/NO972614D0/no
Publication of SE518619C2 publication Critical patent/SE518619C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Detergent Compositions (AREA)
SE9404289A 1994-09-12 1994-12-09 Komposition för reglerad frisättning innehållande monokaproin SE518619C2 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9404289A SE518619C2 (sv) 1994-12-09 1994-12-09 Komposition för reglerad frisättning innehållande monokaproin
JP51754296A JP3487860B2 (ja) 1994-12-09 1995-12-08 逆ミセル（ｌ２）構造または正常ミセル（ｌ１）構造を形成する制御放出組成物
AU42768/96A AU4276896A (en) 1994-12-09 1995-12-08 Controlled release composition forming a reversed micellar (l2) structure or a normal micellar (l1) structure
ES95941306T ES2170171T3 (es) 1994-12-09 1995-12-08 Composicion de liberacion controlada que forma una estructura micelar inversa (l2) o una estructura micelar normal (l1).
FI972415A FI972415A7 (fi) 1994-12-09 1995-12-08 Käänteismiselli-(L2) tai normaalin misellirakenteen (L1) muodostava ko ostumus, josta vapautuminen on säädeltyä
EP95941306A EP0790822B1 (de) 1994-12-09 1995-12-08 MITTEL MIT GESTEUERTER FREISETZUNG, DIE EINE UMGEKEHRTE MICELLARE (L2) STRUKTUR ODER EINE NORMALE MICELLARE (l1) STRUKTUR BILDEN
AT95941306T ATE213932T1 (de) 1994-12-09 1995-12-08 Mittel mit gesteuerter freisetzung, die eine umgekehrte micellare (l2) struktur oder eine normale micellare (l1) struktur bilden
BR9509897A BR9509897A (pt) 1994-12-09 1995-12-08 Composição de liberação controlada para um material biologicamente ativo uso da mesma processo para preparação de uma composição de liberação controlada e para administração a mamíferos especialmente ao homem de um material biologicamante ativo e composição para uso como uma composição medicinal nasal
US08/836,103 US5906831A (en) 1994-09-12 1995-12-08 Controlled release composition forming a reversed micellar (L2) structure or a normal micellar (L1) structure
CA002207218A CA2207218C (en) 1994-12-09 1995-12-08 Controlled release composition forming a reversed micellar (l2) structure or a normal micellar (l1) structure
PCT/SE1995/001479 WO1996017597A1 (en) 1994-12-09 1995-12-08 Controlled release composition forming a reversed micellar (l2) structure or a normal micellar (l1) structure
DE69525761T DE69525761T2 (de) 1994-12-09 1995-12-08 MITTEL MIT GESTEUERTER FREISETZUNG, DIE EINE UMGEKEHRTE MICELLARE (L2) STRUKTUR ODER EINE NORMALE MICELLARE (l1) STRUKTUR BILDEN
NO972614A NO972614D0 (no) 1994-12-09 1997-06-06 Preparat med kontrollert frigivelse som danner en reversert micelle (L2)-struktur eller en normal micelle (L1)-struktur

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9404289A SE518619C2 (sv) 1994-12-09 1994-12-09 Komposition för reglerad frisättning innehållande monokaproin

Publications (3)

Publication Number Publication Date
SE9404289D0 SE9404289D0 (sv) 1994-12-09
SE9404289L SE9404289L (sv) 1996-06-10
SE518619C2 true SE518619C2 (sv) 2002-10-29

Family

ID=20396276

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9404289A SE518619C2 (sv) 1994-09-12 1994-12-09 Komposition för reglerad frisättning innehållande monokaproin

Country Status (13)

Country Link
US (1) US5906831A (de)
EP (1) EP0790822B1 (de)
JP (1) JP3487860B2 (de)
AT (1) ATE213932T1 (de)
AU (1) AU4276896A (de)
BR (1) BR9509897A (de)
CA (1) CA2207218C (de)
DE (1) DE69525761T2 (de)
ES (1) ES2170171T3 (de)
FI (1) FI972415A7 (de)
NO (1) NO972614D0 (de)
SE (1) SE518619C2 (de)
WO (1) WO1996017597A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
DE60221287D1 (de) 2001-11-08 2007-08-30 Atrium Medical Corp Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
AU2002362039B2 (en) * 2001-12-03 2007-07-26 Soligenix, Inc Stabilized reverse micelle compositions and uses thereof
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
EP1811935B1 (de) 2004-09-28 2016-03-30 Atrium Medical Corporation Wärmegehärtetes gel und herstellungsverfahren
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US7670997B2 (en) * 2006-06-08 2010-03-02 Bausch & Lomb Incorporated Ophthalmic compositions comprising a branched, glycerol monoalkyl compound and a fatty acid monoester
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
PL2712622T3 (pl) * 2008-05-21 2017-01-31 Ferring B.V. Ulegająca rozpadowi w ustach desmopresyna do zwiększania początkowego okresu snu niezakłócanego przez nokturię
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9744542B2 (en) 2013-07-29 2017-08-29 Apeel Technology, Inc. Agricultural skin grafting
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016187581A1 (en) 2015-05-20 2016-11-24 Apeel Technology, Inc. Plant extract compositions and methods of preparation thereof
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017048951A1 (en) 2015-09-16 2017-03-23 Apeel Technology, Inc. Precursor compounds for molecular coatings
JP6549326B2 (ja) 2015-12-10 2019-07-24 アピール テクノロジー，インコーポレイテッド 保護コーティングを形成するための植物抽出物組成物
CN109068627B (zh) 2016-01-26 2022-03-18 阿比尔技术公司 用于制备和保存消毒产品的方法
EP3541192B1 (de) 2016-11-17 2025-06-25 Apeel Technology, Inc. Verfahren zur herstellung von fettsäure-estern aus vernetzten polyestern
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US12245605B2 (en) 2018-09-05 2025-03-11 Apeel Technology, Inc. Compounds and formulations for protective coatings
US11641865B2 (en) 2020-03-04 2023-05-09 Apeel Technology, Inc. Compounds and formulations for protective coatings
US11827591B2 (en) 2020-10-30 2023-11-28 Apeel Technology, Inc. Compositions and methods of preparation thereof
WO2022098829A1 (en) * 2020-11-04 2022-05-12 Inolex Investment Corporation Biobased glyceryl heptanoate ester compositions and methods of making and using the same
CN118159138A (zh) 2021-09-08 2024-06-07 阿比尔技术公司 用于保护性涂层的化合物和制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
SE457693B (sv) * 1986-07-01 1989-01-23 Drilletten Ab Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas

Also Published As

Publication number Publication date
DE69525761D1 (de) 2002-04-11
JPH10510260A (ja) 1998-10-06
SE9404289L (sv) 1996-06-10
EP0790822B1 (de) 2002-03-06
CA2207218C (en) 2002-02-12
DE69525761T2 (de) 2002-10-24
SE9404289D0 (sv) 1994-12-09
NO972614L (no) 1997-06-06
FI972415A0 (fi) 1997-06-06
WO1996017597A1 (en) 1996-06-13
NO972614D0 (no) 1997-06-06
ES2170171T3 (es) 2002-08-01
CA2207218A1 (en) 1996-06-13
FI972415L (fi) 1997-06-06
JP3487860B2 (ja) 2004-01-19
FI972415A7 (fi) 1997-06-06
BR9509897A (pt) 1997-12-30
AU4276896A (en) 1996-06-26
EP0790822A1 (de) 1997-08-27
US5906831A (en) 1999-05-25
ATE213932T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
SE518619C2 (sv) Komposition för reglerad frisättning innehållande monokaproin
EP0580778B1 (de) Konvertierbare mikroemulsionsverbindungen
US5688761A (en) Convertible microemulsion formulations
Narang et al. Stable drug encapsulation in micelles and microemulsions
DK2408426T3 (en) Ophthalmic composition based on polyunsaturated omega-3 and omega-6 fatty acids
US20240261254A1 (en) Dihydromyricetin nanoemulsion formulations and methods for forming them
US20040147578A1 (en) Use of lipoaminoacids as absorption promoters in a pharmaceutical composition
EP0746331B1 (de) Konvertierbare mikroemulsionsformulierungen
US6770292B2 (en) Pharmaceutical compositions for oral administration
TW200526200A (en) Therapeutic compositions
JP2002302434A (ja) 新規薬剤デリバリシステム及び脂溶性薬剤用組成物
Agatonovic-Kustrin et al. Strategy for the development of a thermodynamically stable oral microemulsion
US20120252906A1 (en) Bioavailability Enhancement Delivery Composition

Legal Events

Date Code Title Description
NUG Patent has lapsed